{"id":"poliorix","rwe":[],"tags":[],"safety":{"commonSideEffects":["Injection site pain","Injection site redness","Irritability","Fever","Drowsiness"],"contraindications":["Hypersensitivity to any component of the vaccine","Severe allergic reaction to previous dose"]},"trials":[],"_chembl":null,"aliases":["IPV"],"patents":[],"pricing":[],"modality":"Biologic","offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Poliovirus surface antigens","explanation":"Poliorix contains inactivated (killed) poliovirus strains that cannot cause disease but retain their antigenic properties. Upon administration, the vaccine stimulates the body's immune system to produce neutralizing antibodies against the three poliovirus types, providing protective immunity against poliomyelitis infection.","oneSentence":"Inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3."},"_scrapedAt":"2026-03-28T01:29:28.230Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_claudeStub":{"ts":1779138981,"model":"claude-sonnet-4-5-20250929"},"biosimilars":[],"competitors":[{"name":"IPOL","brand":"IPOL","company":"Sanofi Pasteur","rationale":"Inactivated poliovirus vaccine for polio prevention"},{"name":"Infanrix-IPV","brand":"Infanrix-IPV","company":"GlaxoSmithKline","rationale":"Combination vaccine including inactivated polio component"},{"name":"Pentacel","brand":"Pentacel","company":"Sanofi Pasteur","rationale":"Combination vaccine containing inactivated poliovirus vaccine"}],"description":"Poliorix is an inactivated poliomyelitis vaccine developed by GlaxoSmithKline for the prevention of poliomyelitis caused by poliovirus types 1, 2, and 3. The vaccine contains inactivated poliovirus strains and is administered via intramuscular injection to provide active immunization against polio infection.","indications":{"approved":[{"status":"approved","condition":"Poliomyelitis prevention","patientPopulation":"Paediatric and adult populations requiring active immunization"}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01021293","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-28","conditions":"Poliomyelitis, Poliomyelitis Vaccines","enrollment":1101},{"nctId":"NCT01106092","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05-13","conditions":"Haemophilus Influenzae Type b, Tetanus, Hepatitis B","enrollment":312},{"nctId":"NCT01094171","phase":"PHASE4","title":"Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-03","conditions":"Poliomyelitis","enrollment":400},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00937404","phase":"PHASE1","title":"Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-04","conditions":"Poliomyelitis","enrollment":25},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT01323959","phase":"PHASE4","title":"Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-01","conditions":"Acellular Pertussis, Poliomyelitis, Diphtheria","enrollment":212},{"nctId":"NCT01086423","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-01","conditions":"Tetanus, Poliomyelitis, Acellular Pertussis","enrollment":985},{"nctId":"NCT01449812","phase":"PHASE3","title":"Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-01","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":831},{"nctId":"NCT00920439","phase":"PHASE3","title":"Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-01","conditions":"Poliomyelitis","enrollment":26},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT00514033","phase":"","title":"A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Poliomyelitis","enrollment":349}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DERMATITIS ALLERGIC"},{"count":1,"reaction":"ERYTHEMA"},{"count":1,"reaction":"EXPOSURE DURING PREGNANCY"},{"count":1,"reaction":"FACE OEDEMA"},{"count":1,"reaction":"HYPERSENSITIVITY"},{"count":1,"reaction":"INTENTIONAL PRODUCT MISUSE"},{"count":1,"reaction":"TONSILLAR DISORDER"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"Poliorix","genericName":"Poliorix","companyName":"GlaxoSmithKline","companyId":"gsk","firstApprovalDate":"","aiSummary":"Poliorix is an inactivated poliomyelitis vaccine used in combination with other vaccines, such as Infanrix-IPV/Hib and Infanrix Hib, to protect against multiple diseases including poliomyelitis, tetanus, diphtheria, and Haemophilus influenzae type b. It has been studied in clinical trials, including a post-marketing safety study in Korean children, to monitor its safety and reactogenicity.","enrichmentLevel":3,"visitCount":9,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}